Dr Brian Jonas speaks to ecancer about the work he was presenting at the ASCO 2020 Virtual Meeting on timing of response to venetoclax combination treatment in older patients with acute myeloid leukaemia.
Dr Jonas explains that timing of response has become an important question in the field. He reports that most patients quickly achieved remissions quickly, adding that most remissions occurred after 2 cycles of therapy. He explains that they also analysed potential baseline predictive features that may indicate which patients could benefit from additional cycles of treatment.
Dr Jonas concludes that the data set is very informative with regards to informing treatment, but notes that it would be useful to see if real-world data supports their findings.